Innovative strategies in lymphoma therapy

Wiener Klinische Wochenschrift

Volumn 115, Issue 13-14, 2003, Pages 462-470

  Jäger, Ulrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti neoangiogenetic agents; Immunotherapy; Non Hodgkin's lymphoma; Signal transduction inhibitors; Vaccines

Indexed keywords

ALEMTUZUMAB; ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DOXORUBICIN; FLUDARABINE; FR 901228; IBRITUMOMAB TIUXETAN; IODINE 131; MIDOSTAURIN; MITOXANTRONE; MONOCLONAL ANTIBODY; OBLIMERSEN; PREDNISONE; PROTEIN KINASE C INHIBITOR; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

ANGIOGENESIS; ANTIGEN EXPRESSION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; LYMPHOMA; META ANALYSIS; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 18144436954     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03041029     Document Type: Review

References (122)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World health organization classificaton of tumors: tumors of haematiopoietic and lymphoid tissues. IARC Press, Lyon
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006
3. Jäger U, DelleKarth G, Knapp S, Tueni C (1994) Therapy of high-grade non-Hodgkin's lymphoma. Wien Klin Wochenschr 106: 315-320
4. Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J (2002) Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology (Am Soc Hematol Educ Program): 241-262
5. Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 83: 1165-1173
6. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Briere J, Gaulard P, Reyes F (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18: 3025-3030
7. Freedman A, Friedberg JW, Gribben J (2000) High-dose therapy for follicular lymphoma. Oncology (Huntingt) 14: 321-326, 329; discussion 330-332, 338 (Review)
8. Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R (1992) Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80: 1502-1510
9. Levy R (2000) A perspective on monoclonal antibody therapy: where we have been and where we are going. Semin Hematol 37 [4 Suppl 7]: 43-46
10. Grillo-Lopez AJ (2002) Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol 76: 385-393
11. Thieblemont C, Coiffier B (2002) Combination of chemotherapy and monoclonal antibodies for the treatment of lymphoma. Int J Hematol 76: 394-400
12. Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, Behnke D, Wickenhauser C, Schiller P, Diehl V, Engert A (2002) Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 100: 3101-3107
13. Maloney D, Liles T, Czerwinski D, Waldichuck C, Rosenberg J, Grillo-Lopez A, Levy R (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B cell lymphoma. Blood 84: 2457-2466
14. Maloney D, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274
15. Maloney D, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195
16. Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T (2002) Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 16: 2004-2015
17. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833
18. Österborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAM-PATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15: 1567-1574
19. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who failed fludarabine: results of a large international study. Blood 99: 3554-3561
20. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD 3rd, Richards P, Greco FA (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95: 3052-3056
21. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A, Solal-Celigny P (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97: 101-106
22. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 17: 1851-1857
23. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268-276
24. Zinzani PL on Behalf of an Italian Cooperative Study Group on Lymphoma (2002) A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma (FL). Blood 100 [Suppl 1]: Abstract 344
25. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20: 4261-4267
26. Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A (2002) Phase 2 study of combined immunotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100: 3115-3120
27. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santabarbara P, Wacker B, Brettman L (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20: 3891-3897
28. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768
29. DelleKarth G, Laczika K, Scholten C, Lechner K, Jaeger U, Schwarzinger I, Simonitsch I (1995) Clearance of PCR-detectable lymphoma cells from the peripheral blood, but not bone marrow after therapy with campath-1H. Am J Hematol 50: 146-147
30. Keating MJ, O'Brien S, Albitar M (2002) Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 29 [1 Suppl 2]: 70-74
31. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135-3143
32. Foran JM, Rohatiner AZ, Cunningham D, Popescu R, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson P, Gisselbrecht C, Reyes F, Radford J, Bessell E, Souleau B, Benzohra A, Lister TA (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18: 317-324
33. Thomas D, O'Brien S, Cortes J, Faderl S, Fayad L, Garcia-Manero G, Wierda W, Verstovsek S, Kornblau S, Pierce S, Kantarjian H, Keating M (2001) Treatment of splenic lymphoma with villous lymphocytes and marginal zone lymphomas with single agent Rituximab. Blood 98 [Suppl 1]: 134a (Abstract 563)
34. Conconi A, Thieblemont C, Martinelli G, Ferreri A, Devizzi L, Peccatori F, Ponzoni M, Filipazzi V, Dietrich P, Gianni M, Cavalli F, Zucca E (2001) Activity of Rituximab in extranodal marginal zone lymphomas. Blood 98 [Suppl 1]: 807a (Abstract 3354)
35. Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foa R (2001) Efficacy of Mabthera (anti-CD20 Ab) in patients with relapsed/progressed hairy cell leukemia. Haematologica 86: 1046-1050
36. Treon S, Agus T, Link B, Rodrigues G, Molina A, Lacy M, Fisher D, Emmanouilides C, Richards A, Clark B, Lucas M, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson K, Byrd J (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 24: 272-279
37. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92: 1927-1939
38. Ghielmini M, Schmitz SF, Burki K, Pichert G, Betticher DC, Stupp R, Wernli M, Lohri A, Schmitter D, Bertoni F, Cerny T (2000) The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11 [Suppl 1]: 123-126
39. Garnier JL, Stevenson G, Blanc-Brunat N, Touraine JL, Milpied N, Leblond V, Blay JY (2002) Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies. Recent Results Cancer Res 159: 113-22
40. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101: 466-468
41. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19: 2165-2170
42. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19: 2153-2164
43. Hainsworth J, litchy S, Burris H, Greco F (2001) Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma and chronic lymphocytic leukaemia. Blood 98 [Suppl 1]: 363a (Abstract 1530)
44. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B (2001) German chronic lymphocytic leukemia study group: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98: 1326-1331
45. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D (1998) Levels of expression of CD 19 and CD20 in chronic B cell leukemias. J Clin Pathol 51: 364-369
46. Rossmann ED, Lundin J, Lenkei R, Mellsted H, Österborg A (2001) Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2: 300-306
47. Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M (2002) Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood (epub ahead of print)
48. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101: 6-14
49. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10: 655-661
50. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, Uppenkamp M, Willemze R, Mellstedt H (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 16: 3257-3263
51. Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP (2001) Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 18: 99-107
52. Rai K, Hallek M (2002) Future prospects for alemtuzumab (MabCampath). Med Oncol 19 [Suppl]: S57-63
53. Stilgenbauer S, Döhner H (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347: 452-453
54. Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.Blood 98: 1721-1726
55. Birhiray RE, Shaw G, Guldan S, Rudolf D, Delmastro D, Santabarbara P, Brettman L (2002) Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia 16: 861-864
56. Thieblemont C, Bouafia F, Hornez E, Hequet O, Arnaud P, Espinouse D, Salles G, Coiffier B (2002) Maintenance therapy with a monthly injection of campath-1H in refractory chronic leukemia and NHL patients. Blood 100 [Suppl 1]: Abstract 3178
57. Hiddemann W, Forstpointner R, Fiedler F, Gramatzki M, Dörken B, Illiger H, Kneba M, Pfreundschuh M, Parsold R, Parwaresch R, Dreyling M, Unterhalt M for the GLSG (2001) The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamidem, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular and mantle cell lymphomas. Results of a prospective randomised comparison of the GLSG. Blood 98 [Suppl 1]: 844sa (Abstract 3507)
58. Gregory S, Venugopal P, Adler S, O'Brien T, O'Donnell K, Yunis F (2001) Safety and efficacy of fludarabine and mitoxantrone with rituximab consolidation in untreated advanced low grade non Hodgkin's lymphoma. Blood 98 [Suppl 1]: 605a (Abstract 2534)
59. Kimby E, Geisler C, Hagberg H, Holte H, Lehtinen T, Sundström C and on behalf of the Nordic Lymphoma Group (2000) Rituximab as single agent and in combination with interferon-alpha-2a as treatment of untreated and first relapse follicular or other low grade lymphomas: a randomized phase II study. Blood 96 [Suppl 1]: 577a (Abstract 2479)
60. Nabhan C, Tallman MS, Riley MB, Fitzpatrick J, Gordon LI, Gartenhaus R, Kuzel T, Siegel R, Rosen ST (2001) Phase I study of rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 98 [Suppl 1]: 365a (Abstract 1536)
61. Faderl S, Thomas DA, O'Brien S, Giles F, Koller CA, Beran M, Williams M, Garcia-Manero G, Kantarjian HM, Keating MJ (2001) An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and rituximab in the treatment of CD52- and CD20-positive chronic lymphoid disorders. Blood 98 [Suppl 1]: 365a (Abstract 1537)
62. Leonard JP, Coleman M, Matthews JC, Fiore JM, Dosik A, Kapushoc H, Kin E, Cesano A, Wegener WA, Goldenberg DM (2001) Combination monoclonal antibody therapy for lymphoma: treatment with epratuzumab (anti-CD22) and rituximab (anti-CD20) is well tolerated. Blood 98 [Suppl 1]: 844a (Abstract 3506)
63. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242
64. Spina M, Sparano JA, Jaeger U, Rossi G, Tirelli U (2003) Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS 17: 137-138
65. Winkler U, Jensen M, Manzke O, Schultz H, Diehl V, Engert A (1999) Cytokine release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94: 2217-2224
66. Skrabs C, Muller C, Agis H, Mannhalter C, Jager U (2002) Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 16: 1884-1886
67. Cheson BD (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101: 391-398
68. Witzig TE, White CA, Wiseman GA (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17: 3793-3803
69. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19: 3918-3928
70. 90Y Zevalin™ (90)yttrium ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nuclear Med 27: 766-777
71. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20: 3262-3269
72. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463
73. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99: 4336-4342
74. Murray JL, Witzig TE, Wiseman GA (2000) Zevalin therapy can convert peripheral blood bcl-2 status from positive to negative in patients with low-grade, follicular or transformed non-Hodgkin's lymphoma (NHL). J Clin Oncol 19: Abstract 22a
75. 90Yttrium ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20: 3885-3890
76. Kaminski MS, Estes J, Zasadry KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL (2000) Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259-1266
77. Kaminski MS, Press OW, Lister TA, Valente NK, Kroll S, Tidmarsh G (1999) Iodine 1131 tositumomab for patients with small lymphocytic lymphoma (SLL): overall clinical trial experience. Blood 94 [Suppl 1]: Abstract 88a-89a
78. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18: 1316-1323
79. Horning SJ, Lucas JB, Younes A (2000) Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multicenter phase II study. Blood 96 [Suppl 1]: Abstract 508a
80. Press OW, Unger JM, Braziel R, et al (2001) A phase II trial of CHOP followed by Bexxar™ (tositumomab and iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911). Blood 98: Abstract 843a
81. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Thomas ED, Bernstein ID (1995) Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336-340
82. Sheikh MS (2002) Spotlight on molecular targeted therapy: introduction. Leukemia 16: 431-432
83. Almond JB, Cohen GM (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443
84. Lee JT Jr, McCubrey JA (2002) The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukaemia. Leukemia 16: 486-507
85. Garg A, Aggarwal BB (2002) Nuclear transcrition factor-κB as a target for cancer drug development. Leukemia 16: 1053-1068
86. Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7: 9-16
87. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhbitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076
88. Harper JW (2002) A phosphorylation driven ubiquitination switch for cell cycle control. Trends Cell Biol 12: 104-107
89. Bertoni F, Cavalli F, Cotter FE, Zucca E (2002) Genetic alterations underlying the pathogenesis of malt lymphoma. Hematol J 3: 10-13
90. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM (2002) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511
91. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC (2002) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101: 2377-2380
92. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20: 4420-4427
93. Sandor V, Senderowicz A, Sackett D (1998) Depsipeptide causes G1 cell cycle arrest through disruption of signal transduction through MAP kinase. Proc Am Assoc Cancer Res 39: A3812
94. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR (1999) Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94: 1401-1408
95. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865-2868
96. Virchis A, Ganeshaguru K, Hart S, Jones D, Fletcher L, Wright F, Wickremasinghe R, Man A, Csermak K, Meyer T, Fabbro D, Champain K, Yap A, Prentice HG, Mehta A (2002) A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol J 3: 131-136
97. Sawyer TK, Bohacek RS, Dalgarno DC, Eyermann CJ, Kawahata N, Metcalf CA 3rd, Shakespeare WC, Sundaramoorthi R, Wang Y, Yang MG (2002) SRC homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev Med Chem 2: 475-488
98. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKeam JP, Korsmeyer SJ (1989) bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation Cell 57: 79-88
99. Miyashita T, reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157
100. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18: 1812-1823
101. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4: 232-234
102. Giles FJ (2002) The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt) 16 [5 Suppl 4]: 23-29
103. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, Vitelli G, Tucci L, Roccaro AM, Dammacco F (2002) Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukaemia. Blood 100: 3344-3351
104. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16-19
105. Cavenagh JD, Oakervee H (2003) Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 120: 18-26
106. Wilson EA, Jobanputra S, Jackson R, Parker AN, McQuaker IG (2002) Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. Br J Haematol 119: 128-130
107. Drach J, Kaufmann H, Puespoek A, Bankier A, Urbauer E, Chott A, Raderer M (2002) Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. Blood 100 [Suppl 1]: Abstract 606
108. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100: 1168-1171
109. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327: 1209-1215
110. Stevenson FK, Rosenberg W (2001) DNA vaccination: a potential weapon against infection and cancer. Vox Sang 80: 12-18
111. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58
112. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5: 1171-1177
113. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99: 1517-1526
114. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917-2924
115. Mitterbauer M, Neumeister P, Kalhs P, Brugger S, Fischer G, Dieckmann K, Hoecker P, Hinterberger W, Linkesch W, Simonitsch I, Jaeger U, Lechner K, Mannhalter C, Mitterbauer G, Greinix HT (2001) Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 15: 635-641
116. Bertz H, Illerhaus G, Veelken H, Finke J (2002) Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 13: 135-139
117. Shaffer AL, Rosenwald A, Staudt LM (2002) Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2: 920-932
118. Gaiger A, Carter L, Mannion-Henderson J, Ordonez N, Kusec R, Jaksic B, Molesh D, Jaeger U, Reed S, Cheever MA, Algate P (2001) Identification of genes associated with B-cell and T-cell neoplasms using a combination of cDNA PCR subtraction and microarray analysis. Blood 98 [Suppl 1]: Abstract 1389
119. Antonucci F, Chilosi M, Santacatterina M, Herbert B, Righetti PG (2002) Proteomics and immunomapping of reactive lymph-node and lymphoma. Electrophoresis 23: 356-362
120. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758
121. Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH, Heerema NA (2003) Interphase cytogenetic abnormalities in chronic lymphocytic leukaemia may predict response to rituximab. Cancer res 63: 36-38
122. Couzin J (2002) Breakthrough of the year. Small RNAs make big splash. Science 298: 2296-2297